Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study.

Redondo, Andrés; Ramos Vázquez, Manuel; Manso, Luis; Gil Gil, Miguel J; Garau Llinas, Isabel; García-Garre, Elisa; Rodríguez, César A; Chacón, José Ignacio; López-Vivanco, Guillermo

Redondo, Andrés; Ramos Vázquez, Manuel; Manso, Luis; Gil Gil, Miguel J; Garau Llinas, Isabel; García-Garre, Elisa; Rodríguez, César A; Chacón, José Ignacio; López-Vivanco, Guillermo.

Afiliação

Redondo A; Clinical Oncology Department, Hospital Universitario La Paz, Madrid, Spain, andres.redondos@uam.es.
Ramos Vázquez M; Centro Oncológico de Galicia, A Coruña, Spain.
Manso L; Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
Gil Gil MJ; Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Spain.
Garau Llinas I; Hospital Son Llatzer, Palma de Mallorca, Spain.
García-Garre E; Hematology and Medical Oncology Department, University Hospital Morales Meseguer, Murcia, Spain.
Rodríguez CA; Oncology Department, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.
Chacón JI; Medical Oncology Department, Hospital Virgen de la Salud, Toledo, Spain.
López-Vivanco G; Department of Medical Oncology, Hospital Universitario Cruces, Barakaldo, Spain.

Onco Targets Ther ; 11: 5845-5852, 2018.

Article em En | MEDLINE | ID: mdl-30271167

Palavras-chave

bevacizumab; maintenance hormonal therapy; metastatic breast cancer; real-world; taxane

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Idioma: En Revista: Onco Targets Ther Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google